Antibiotic/COPD in Acute Exacerbation of Chronic Obstructive Pulmonary Disease (COPD) Requiring Mechanical Ventilation
Primary Purpose
Chronic Obstructive Pulmonary Disease, Sepsis, Antibiotics
Status
Completed
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
ciprofloxacin
trimethoprim-sulfamethoxazole
Sponsored by
About this trial
This is an interventional treatment trial for Chronic Obstructive Pulmonary Disease focused on measuring chronic obstructive pulmonary disease, pulmonary infection, antibiotic
Eligibility Criteria
Inclusion Criteria:
- All patients having a COPD (according to the definition of the American Thoracic Society) and having an acute exacerbation leading to an acute respiratory failure requiring the admission to ICU and mechanical ventilation.
- The acute exacerbation of COPD is defined by increase in the frequency of cough, the volume and the purulence of expectoration and increase of baseline dyspnea. To be included, patients must have respiratory rate >30 cycles/min and one of the following blood gas criteria (with blood gases performed right before the initiation of mechanical ventilation): PaC02 > 6kPa and arterial pH <7.30.
Exclusion Criteria:
- Pneumonia documented with chest radiography
- Antibiotic treatment in the ten previous days of ICU admission
- Former inclusion in the study
- History of allergy to the quinolones and/or to trimethoprim sulfamethoxazole
- Pregnancy or breast feeding
- Severe chronic disease: heart, liver, kidney.
- Known immunodeficiency (malignant hemopathy, AIDS...)
- Digestive disease which could affect the absorption of the drugs
- Concomitant infection which requires systemic antibiotic treatment
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
Ciprofloxacin
trimethoprim-sulfamethoxazole
Arm Description
750 mg a day during 10 days
2000 mg a day for 10 days
Outcomes
Primary Outcome Measures
Two major criteria will be used for the determination of sample size and the estimate of the effectiveness of the treatments of the study: 1. mortality (in ICU and in the hospital) 2. rate of additional antibiotherapy course.
The decision to initiate new antibiotics was left to the discretion of the treating physician, and if resistant species were cultured, the protocol treatment was not systematically changed unless the clinical course of the patient worsened
Secondary Outcome Measures
Mechanical ventilation duration
duration of mechanical ventilation
Duration of hospital stay
duration of hospital stay
Full Information
NCT ID
NCT00791505
First Posted
November 12, 2008
Last Updated
February 20, 2020
Sponsor
University of Monastir
1. Study Identification
Unique Protocol Identification Number
NCT00791505
Brief Title
Antibiotic/COPD in Acute Exacerbation of Chronic Obstructive Pulmonary Disease (COPD) Requiring Mechanical Ventilation
Official Title
Antibiotic Comparison Exacerbation COPD
Study Type
Interventional
2. Study Status
Record Verification Date
February 2020
Overall Recruitment Status
Completed
Study Start Date
July 2002 (undefined)
Primary Completion Date
June 2005 (Actual)
Study Completion Date
June 2005 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Monastir
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Although the use of antibiotics in the treatment of acute exacerbation of chronic obstructive pulmonary disease (COPD) is largely accepted, controversy remains regarding whether the choice of antibiotic has any impact on outcome. Our aim was to compare the effects of the combination of trimethoprim and sulfamethoxazole and ciprofloxacin in patients treated for severe COPD exacerbation requiring mechanical ventilation.
Detailed Description
Antibiotic therapy has been shown to be beneficial in patients with severe acute exacerbation of chronic obstructive pulmonary disease (COPD). Although recent guidelines support the use of new antibiotics there is no evidence that newer antibiotics are any better than older agents. The choice of antibiotic to be used in this situation is challenging to the clinician who must choose between traditional antibiotics (cyclins, aminopénicillins, cotrimoxazole...) and new antimicrobial agents. Indeed, available comparative studies did not show an obvious superiority of new antibiotics compared to their predecessors . Taking into account bacterial agents associated to COPD exacerbations, one must choose an antibiotic which has the best activity against Haemophilus influenzae, Streptococcus pneumoniae and Branhamella catarrhalis. News quinolones are represented as an interesting alternative to standard antibiotics because of their large spectrum of action and of their pharmacokinetic advantages allowing high tissue penetration in the pulmonary parenchyma and tracheobronchial tree. Data on their use among patients having moderate exacerbation of COPD are encouraging but their effectiveness in more severe presentations is not established. The objective of this randomized controlled and double blind study is to evaluate the effectiveness and tolerance of ciprofloxacin compared to trimethoprim sulfamethoxazole in patients admitted to ICU for severe exacerbation of COPD requiring mechanical ventilation.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Chronic Obstructive Pulmonary Disease, Sepsis, Antibiotics
Keywords
chronic obstructive pulmonary disease, pulmonary infection, antibiotic
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
170 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Ciprofloxacin
Arm Type
Active Comparator
Arm Description
750 mg a day during 10 days
Arm Title
trimethoprim-sulfamethoxazole
Arm Type
Active Comparator
Arm Description
2000 mg a day for 10 days
Intervention Type
Drug
Intervention Name(s)
ciprofloxacin
Other Intervention Name(s)
fluoroquinolone
Intervention Description
1500 mg a day for 10 days
Intervention Type
Drug
Intervention Name(s)
trimethoprim-sulfamethoxazole
Other Intervention Name(s)
sulfatrim, bactrim
Intervention Description
2000 mg a day for 10 days
Primary Outcome Measure Information:
Title
Two major criteria will be used for the determination of sample size and the estimate of the effectiveness of the treatments of the study: 1. mortality (in ICU and in the hospital) 2. rate of additional antibiotherapy course.
Description
The decision to initiate new antibiotics was left to the discretion of the treating physician, and if resistant species were cultured, the protocol treatment was not systematically changed unless the clinical course of the patient worsened
Time Frame
30 day after starting protocol
Secondary Outcome Measure Information:
Title
Mechanical ventilation duration
Description
duration of mechanical ventilation
Time Frame
30 days after starting protocol
Title
Duration of hospital stay
Description
duration of hospital stay
Time Frame
30 days after starting protocol
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
All patients having a COPD (according to the definition of the American Thoracic Society) and having an acute exacerbation leading to an acute respiratory failure requiring the admission to ICU and mechanical ventilation.
The acute exacerbation of COPD is defined by increase in the frequency of cough, the volume and the purulence of expectoration and increase of baseline dyspnea. To be included, patients must have respiratory rate >30 cycles/min and one of the following blood gas criteria (with blood gases performed right before the initiation of mechanical ventilation): PaC02 > 6kPa and arterial pH <7.30.
Exclusion Criteria:
Pneumonia documented with chest radiography
Antibiotic treatment in the ten previous days of ICU admission
Former inclusion in the study
History of allergy to the quinolones and/or to trimethoprim sulfamethoxazole
Pregnancy or breast feeding
Severe chronic disease: heart, liver, kidney.
Known immunodeficiency (malignant hemopathy, AIDS...)
Digestive disease which could affect the absorption of the drugs
Concomitant infection which requires systemic antibiotic treatment
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
nouira semir, MD
Organizational Affiliation
research unit 04/UR/08-20
Official's Role
Principal Investigator
12. IPD Sharing Statement
Citations:
PubMed Identifier
20536364
Citation
Nouira S, Marghli S, Besbes L, Boukef R, Daami M, Nciri N, Elatrous S, Abroug F. Standard versus newer antibacterial agents in the treatment of severe acute exacerbation of chronic obstructive pulmonary disease: a randomized trial of trimethoprim-sulfamethoxazole versus ciprofloxacin. Clin Infect Dis. 2010 Jul 15;51(2):143-9. doi: 10.1086/653527.
Results Reference
derived
Learn more about this trial
Antibiotic/COPD in Acute Exacerbation of Chronic Obstructive Pulmonary Disease (COPD) Requiring Mechanical Ventilation
We'll reach out to this number within 24 hrs